Please assess the completion status of the following clinical trial:

Trial Title: Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female from 2 to \<15 years of age.~* Require treatment for the prevention of systemic fungal infection.~* Expected to develop neutropenia (ANC \<500 cells/uL) lasting more than 10 days following chemotherapy.~* Anticipated to live for more than 3 months.~Exclusion Criteria:~* Evidence of any clinically significant liver or renal function or other abnormalities such as cardiac arrhythmia, hypokalemia, hypomagnesemia or hypocalcemia.~* Documented bacterial or viral infection not responding to appropriate treatment.~* Hypersensitivity to or severe intolerance of azole antifungal agents.~* Receiving other azoles or drugs that is are prohibited in the voriconazole label or associated.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1.0 (Type: EXPERIMENTAL): Immunocompromised children aged 2 to \<15 and 12 to \<15 years weighing \<50 kg who are at high risk for systemic fungal infection.
- 2.0 (Type: EXPERIMENTAL): Immunocompromised children aged 12 to \<15 years weighing more than 50 kg who are at high risk for systemic fungal infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).